Modified MTSP-1 Polypeptides for Complement Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic strategies for inhibiting complement activation in diseases mediated by the complement system, such as autoimmune diseases and inflammatory disorders, face limitations due to short half-lives of small molecules and immune responses to therapeutic antibodies, necessitating the development of more effective and stable inhibitors.

Innovation Solution

Modified MTSP-1 polypeptides with specific amino acid modifications, such as I41S, Q38H, D60bT, and F60eS, are designed to cleave complement protein C3, thereby inhibiting complement activation, with enhanced activity and stability through conjugation to moieties like PEGylation for improved pharmaceutical properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If small molecules are used to inhibit complement activation, then complement inhibition is achieved, but the therapeutic duration is limited due to short half-lives

Engineering Contradiction:

Improvecomplement inhibition efficacyVSAvoidtherapeutic duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention changes the molecular parameters by transitioning from small molecule inhibitors to modified MTSP-1 polypeptides with specific amino acid substitutions (I41S, Q38H, D60bT, F60eS). These parameter changes in molecular structure result in extended half-life and improved therapeutic duration while maintaining complement inhibition efficacy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite therapeutic agents by conjugating MTSP-1 polypeptides with PEG (polyethylene glycol) and other moieties. This composite approach extends the half-life of the therapeutic agent in circulation, thereby improving the duration of action without compromising the complement inhibition function

Inventive Principle:

Principle #40Composite materials

2Reliability

If therapeutic antibodies are used to inhibit complement activation, then complement inhibition is achieved, but immune responses are triggered

Engineering Contradiction:

Improvecomplement inhibition efficacyVSAvoidimmune response

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Instead of using foreign antibodies that trigger immune responses, the invention uses modified versions of the endogenous MTSP-1 protein. By copying and modifying the natural human protein structure (with specific amino acid substitutions), the therapeutic agent maintains complement inhibition efficacy while being recognized as self by the immune system, thereby avoiding immune responses

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The invention converts the potential harm of immune recognition into a benefit by using endogenous protein sequences. The MTSP-1 polypeptide, being derived from human protein, naturally evades immune detection while maintaining its inhibitory function against complement activation, thus turning the potential disadvantage of protein-based therapy into an advantage

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If MTSP-1 polypeptides are modified with amino acid substitutions, then cleavage activity toward C3 is enhanced, but structural complexity increases

Engineering Contradiction:

Improvecleavage activityVSAvoidpolypeptide structure

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The invention applies local quality changes by introducing specific amino acid substitutions at particular positions (I41S, Q38H, D60bT, F60eS) within the MTSP-1 polypeptide structure. These localized modifications enhance cleavage activity toward C3 without requiring global structural changes, thereby improving productivity with minimal increase in overall complexity

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified MTSP-1 polypeptides demonstrate increased activity in cleaving C3, providing effective inhibition of complement activation, which can treat various diseases mediated by complement system dysregulation, including autoimmune and inflammatory conditions, with improved stability and reduced immune response.

Implementation Method 1

the modified MTSP-1 polypeptide cleaves a complement protein to thereby inhibit or reduce complement activation

Methodology Applied

Scientific EffectProteolysis: Hydrolysis

Data Source

PatentUS12173337B2Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

Publication Date: 2024.12.24 VERTEX PHARMACEUTICALS INC

AI summary

Provided are MTSP-1 polypeptides modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation. The modified MTSP-1 polypeptides that inhibit complement activation can be used for treatment of diseases and conditions in which complement activation plays a role. Such diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Exemplary of these disorders are ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal delayed graft function (DGF).